Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9382074 | 0.81 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL9385930 | 0.79 | PRMT5 (0.42) | — | |
| SCHEMBL17926590 | 0.78 | CSNK2A2 (0.39) | — | |
| SCHEMBL24476352 | 0.77 | CSNK2A1 (0.35) | — | |
| SCHEMBL24476481 | 0.76 | CSNK2A1 (0.34) | — | |
| SCHEMBL24476342 | 0.76 | CSNK2A1 (0.34) | — | |
| SCHEMBL24476628 | 0.76 | CSNK2A1 (0.34) | — | |
| SCHEMBL24476527 | 0.73 | CSNK2A1 (0.42) | — | |
| SCHEMBL28648960 | 0.73 | CYP1A2 (0.36) | — | |
| SCHEMBL16506387 | 0.72 | XIAP (0.35) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| US-20220168309-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | INVOX PHARMA LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| US-20220168309-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | INVOX PHARMA LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| EP-3934652-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | F-Star Therapeutics, Inc. (GB) | 2022-01-12 | — | — | EP | disclosed |
| CN-113645977-A | Compounds, compositions and methods for treatment of disease | F-星治疗公司 | 2021-11-12 | — | — | CN | disclosed |
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7524847-B2 | Fused 1,3-dihydro-imidazole ring compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | EISAI CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | MYT1, AQP4, AQP1 | DPP4 2329/4885 |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | DPP4 91/4885 |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | DPP4 1/4885 |
| US-20220168309-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | STING1, CGAS, MAVS | DPP4 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.